



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of: **Maurizio Zanetti**
Serial No.: 09/788,110
Filed: 02/15/2001
Entitled: **A Universal Vaccine and Method for Treating Cancer Employing Telomerase Reverse Transcriptase**

Group No.: 1642
Examiner: Ungar, S.

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: June 13, 2006

By: _____

Cliff Cannon-Cin
Cliff Cannon-Cin

Dear Madam:

The citations listed below, copies attached, may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. § 1.56 and § 1.97. The Examiner is requested to make these citations of official record in this application.

The following printed publications were cited in the Partial European Search Report of a related application (EP 01 91 2787):

- WO 99/50392 of Gaeta *et al.*, "Methods and compositions for eliciting an immune response to a telomerase antigen (October 7, 1999);
- WO 00/02581 of Gaudernack *et al.*, "Antigenic peptides derived from telomerase," (January 20, 2000);
- WO 00/61766 of Agrawal *et al.*, "Telomerase-specific cancer vaccine," (October 19, 2000);

- Vonderheide *et al.*, "Search for universal tumor antigens: Potential of the catalytic telomerase subunit," *Blood*, 92(10Supp):500A, abstract# 2058 (November 15, 1998); and
- Vonderheide *et al.*, "Generation of telomerase-specific HLA-A3-restricted cytotoxic T lymphocytes from patient blood: Implications for widely applicable anti-cancer immunotherapy," *Blood*, 94(10Supp):677A, abstract #2999 (November 15, 1999).

This Information Disclosure Statement under 37 C.F.R. § 1.56 and § 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: June 13, 2006



Christine A. Lekutis
Registration No. 51,934

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
415.904.6500

(Modified)

U.S. Department of Commerce
Patent and Trademark Office

Serial No.: 09/788,110

(Use Reverse Side If Necessary)

(37 CFR § 1.98(b))

Filing or 371(c) Date: 02/15/2001

Group Art Unit: 1642

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date

[illegible][illegible]

Date Considered:

EXAMINER:Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.